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Edited by Varda RotterAbstract Although mutation of p53 tumor-suppressor gene is
rare in nasopharyngeal carcinoma (NPC), NPC has a high fre-
quency of overexpression of p53 protein. There seem to be com-
plex mechanisms of inactivation and stabilization of p53 in NPC.
To detect proteins associated with the function of p53 in high
throughout screening, we succeeded in establishing p53 knock-
down human NPC CNE2 cell line (CNE2sip53) using stable
RNA interference, and compared the proteomic changes between
CNE2sip53 and control cell line CNE2/pSUPER using two-
dimensional gel electrophoresis. Twenty-two diﬀerentially ex-
pressed proteins between the two cell lines were identiﬁed by both
matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry and electrospray ionization tandem mass spectrom-
etry, some of which are known to be associated with the p53
function (HSP27, hnRNP K, 14-3-3r, etc.), and others may be
novel proteins associated with p53 function (eIF4B, TPT1,
hnRNP H3, SFRS1 etc.). Furthermore, several diﬀerential pro-
teins including HSP27, HSP70, GRP75 and GRP78 were veri-
ﬁed as p53 interacting proteins in NPC by immunoprecipitation
and Western blot analysis, and the suppression of HSP27
expression by HSP27 antisense oligonucleotides could decrease
the p53 protein level. Our data suggest that these diﬀerential
proteins may be associated with the function of p53 in NPC,
and provide new clues to elucidate the mechanisms of inactiva-
tion and stabilization of p53 in NPC.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Nasopharyngeal carcinoma (NPC) is a high-incidence malig-
nancy in southern China, Southeast Asia, northern Africa, and
Alaska [1]. According to current studies on the origin of NPC,
genetic alterations involving tumor suppressor genes and pro-
to-oncogenes in multiple cellular pathways are believed to be
important in multistage NPC carcinogenesis.
p53 tumor-suppressor protein plays a pivotal role in regulat-
ing cell cycle, diﬀerentiation and apoptosis [2]. Mutation of
p53 gene detected in more than 50% of human tumors has been
found to be the most frequent molecular alteration in human
malignancy, but it is rare in NPC. Most studies indicated
although NPC had a low frequency of p53 mutations, overex-
pression or accumulation of p53 protein in NPC was up to
95%, and overexpressed p53 protein in NPC might lose its
tumor suppressor activity and contribute to cellular immortal-
ization and transformation [3–5]. Previous studies indicated
that the abnormal expressions of p53 interacting proteins such
as MDM2 play a very important role in stabilization of p53
and subsequent blockage of p53 function [6]. Heat shock pro-
teins (HSPs), as molecular chaperones and cell protectors from
all kinds of noxious stimuli have been widely investigated in
many cancers as to its relationships with p53 [7,8]. It is re-
ported that HSP70 could interact with and inactivate wild-type
p53 by nuclear exclusion and play a role in malignant transfor-
mation [9]. These suggest that complex mechanisms of inacti-
vation and stabilization of p53 may be also operating in
NPC cells.
Proteomics is an eﬀective platform to globally detect and
characterize proteins. Comparative proteomic approach is
the main strategy of proteomics to analyze and compare the
diﬀerentially expressed proteins. On the other hand, RNA
interference (RNAi), as a sequence-speciﬁc and posttranscrip-
tional gene silencing method initiated by double-stranded
RNAs is increasingly being used to speciﬁcally inhibit gene
expression in mammalian cells to determine the functions of
speciﬁc genes [10]. Thus, we used stable expression of small
interfering RNAs (siRNA) of p53 gene to inhibit the expres-
sion of p53 in human undiﬀerentiated NPC cell line CNE2,
which was reported the detection of overexpressed p53 protein.
And then comparative proteomic approach was performed to
identify the diﬀerential proteins between p53 knockdown
CNE2 and control cells, which may be associated with p53
function.blished by Elsevier B.V. All rights reserved.
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which had stable expression p53 siRNA and satisfactory inhi-
bition of the target p53 expression, and used two-dimensional
gel electrophoresis (2-DE) to detect the diﬀerentially expressed
proteins between CNE2sip53 and control cell line CNE2/pSU-
PER. The diﬀerential expression proteins between the two cell
lines were identiﬁed by both matrix-assisted laser desorption/
ionization time-of-ﬂight mass spectrometry (MALDI-TOF-
MS) and electrospray ionization-quadruple time-of-ﬂight
MS/MS (ESI-Q-TOF-MS). Furthermore, the relationships of
partial identiﬁed diﬀerential proteins with p53 in NPC were
studied by immunoprecipitation and Western blot analysis,
as well as antisense oligonucleotides transfection. The results
presented here will no doubt provide clues to further study
the functional mechanism of p53 in NPC.2. Materials and methods
2.1. Construction of recombinant pSUPER plasmid expressing p53-
siRNA
pSUPER vector (a gift from Doctor Yan Li, University of Texas
MD. Andersion Cancer Center, USA), which contains polymerase-
III H1-RNA gene promoter, can direct the synthesis of siRNA-like
transcripts. The target sequence for p53 (GenBank Accession No.
AH007667) was chemically synthesized (TakaRa, Japan) as comple-
mentary oligonucleotides [11]. BLAST search of the human genome
database was carried out to ensure the sequence not to target other
gene transcripts. The synthetic oligonucleotides sip53a: 5 0-gatcccc-
GACTCCAGTGGTAATCTACttcaagagaGTAGATTACCACTGG-
AGTCtttttggaaa-3 0; and sip53s: 5 0-agcttttccaaaaaGACTCCAGTGG-
TAATCTACtctcttgaaGTAGATTACCACTGGAGTCggg-3 0 were
annealed and cloned down-stream of H1 promoter to construct re-
combinant pSUPER/sip53 plasmid. The cloned p53 target sequence
was sequence-conﬁrmed by DNA sequencing using 377 Prism auto-
mated DNA sequencer.
2.2. Cell culture and stable transfection
CNE2 cell line derived from human undiﬀerentiated NPC was ob-
tained from the Cancer Institute, Chinese Academy of Medical Sci-
ences. CNE2 cells were grown at 37 C in RPMI 1640 medium
(Gibico BRL, Grand Island, New York, USA) supplemented with
10% heat-inactivated fetal bovine serum (Gibico BRL, Grand Island,
New York, USA), 100 U/ml penicillin (Gibico BRL, Grand Island,
New York, USA) and 100 lg/ml streptomycin (Gibico BRL, Grand
Island, New York, USA ) in a 5% CO2-humidiﬁed chamber. The
day before transfection, 1 105 cells were trypsinized, diluted with
fresh medium without antibiotics, and plated per well of six-well tissue
culture plates. The following day, cells were transfected with pSUPER/
sip53 plasmid and with pSUPER vector as control by using Oligofec-
tamine transfection reagent (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. Puromycin resistance clones
were selected in the medium containing 2 lg/ml puromycin (Sigma–Al-
drich Co., St. Louis, MO, USA) for two weeks. The positive clones
were picked and expanded to establish cell lines, and stable transfec-
tion cell lines expressing p53 siRNA were determined by Western blot
analysis.
2.3. Western blot analysis
The cells were harvested from ﬂasks, and lysed in a lysis buﬀer
(50 mM Tris, pH 7.4, 100 mM NaCl, 1 mM MgCl2, 2.5 mM Na3VO4,
1 mM PMSF, 2.5 mM EDTA, 0.5% Triton X-100, 0.5% NP-40, 5 lg/
mL of aprotinin, pepstatin A, and leupeptin) for 60 min on ice. Protein
samples (500 lg) were separated on 10% or 12% SDS–PAGE gels, and
transferred to Hybond-P PVDF membranes (Amersham Biosciences,
Stockholm, Sweden). After blocking with 5% non-fat dry milk in
TBS-T buﬀer (20 mM Tris, pH 7.6, 100 mM NaCl, 0.1% Tween-20)
for 2 h at room temperature, the membranes were probed with
1:1000 dilution of anti-p53 (DO-1, Santa Cruz Biotechnology, CA,
USA) overnight at 4 C, and probed with 1:5000 dilution of anti-b-Ac-tin (AC-15, Sigma–Aldrich) to correct for diﬀerences in protein load-
ing, followed by incubation in a 1:2000 dilution of secondary
antibodies conjugated to horseradish peroxidase (Amersham Biosci-
ences) for 1 h at room temperature. Protein bands were detected using
ECL detection system (Amersham Biosciences). All of the western
immunoblots were performed at least three times.
2.4. 2-DE
Monolayer cultures of two cell lines CNE2sip53 and CNE2/pSU-
PER were harvested, and lysed in lysis buﬀer (7 M urea, 2 M thiourea,
100 mM DTT, 4% Chaps, 40 mM Tris, 2% Pharmalyte, 1 mg/ml
DNase I). After incubated at 37 C for 1 h, the lysates were centrifuged
at 15000 rpm for 30 min at 4 C. The supernatant was transferred and
the concentration of the total proteins was determined using 2D Quan-
tiﬁcation kit (Amersham Biosciences). Triplicate gels were made for
each cell line and a total amount of 1.0 mg of protein per gel was ana-
lyzed. Protein samples were diluted to 450 ll with rehydration solution
[7 M urea, 2 M thiourea, 0.2% DTT, 0.5% (v/v) Ph4-7 IPG buﬀer
(Amersham Biosciences), and trace bromophenol blue] and applied
to IPG strips (pH 4–7L, 240 mm · 3 mm · 0.5 mm, Amersham Biosci-
ences) by 24 h rehydration at 30 V. Then proteins were focused succes-
sively for 1 h at 500 V, 1 h at 1000 V and 8.5 h at 8000 V to give a total
of 68 kVh on an IPGphor (Amersham Biosciences). Focused IPG
strips were equilibrated for 15 min in a solution (6 M urea, 2% SDS,
30% glycerol, 50 mM Tris–HCl, pH 8.8 and 1%DTT), and then for
an additional 15 min in the same solution except that DTT was re-
placed by 2.5% iodoacetamide (Sigma–Aldrich). After equilibration,
second-dimension sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE) was performed on Ettan DALT II system
(Amersham Biosciences). After SDS–PAGE, the Blue Silver staining
method, a modiﬁed Neuhoﬀ’s colloidal coomassie blue G-250 (Amer-
sham Biosciences) stain, was used to visualize the protein spots in the
2-DE gels [12].
2.5. Gel scanning and image analysis
The stained 2-DE gels were scanned with MagicScan software on
Imagescanner (maximum resolution 9600 · 9600 dpi) (Amersham Bio-
sciences), and analyzed using PDQuest system (Bio-Rad Laboratories,
Hercules, CA, USA) according to the protocols provided by the man-
ufacturer. To minimize the contribution of experimental variations,
three separate gels were prepared for each cell line. The gel spot pattern
of each gel was summarized in a standard after spot matching. Thus,
we obtained one standard gel for each cell line. Spot intensities were
quantiﬁed by calculation of spot volume after normalization of the im-
age using the total spot volume normalization method multiplied by
the total area of all the spots. The change index was deﬁned as the ratio
between the spot percentage relative volumes in CNE2sip53 and
CNE2/pSUPER cell lines. All indexes were calculated based on the
mean of the spot intensities of all six gels, with standard deviations.
Proteins were classiﬁed as being diﬀerentially expressed between the
two cell lines when spot intensity was showed a diﬀerence P 2-fold
variation in CNE2sip53 in comparison to CNE2/pSUPER. Signiﬁcant
diﬀerences in protein expression levels were determined by Student’s t-
test with a set value of P < 0:05.
2.6. Protein identiﬁcation by MALDI-TOF-MS and ESI-Q-TOF-MS
Selected diﬀerential protein spots were excised from preparative gels
using punch and in-gel digestion was performed. The gel-spots were
washed three times with two-distillation water and destained with
the fresh solution containing 100 mM NH4HCO3 in 50% acetonitrile
at 37 C. After dried in a vacuum centrifuge, the gel-pieces were incu-
bated in 10 ll digestion solution consisted of 40 mM NH4HCO3 in 9%
acetonitrile solution, and 20 lg/ml proteomics grade trypsin (Promega,
USA) for 10–12 h at 37 C. The tryptic peptide mixture was extracted
and puriﬁed with Millipore ZipTip C18 column (Millipor, Bedford,
MA, USA). The puriﬁed tryptic peptide mixture was mixed with con-
taining a-cyano-4-hydroxycinnamic (CCA) (Sigma–Aldrich Co.)
matrix solution and vortexed gently. A volume (1 ll) of the mixture
CCA matrix was loaded on a stainless steel plate and air-dried, and
then was analyzed with Voyager System DE-STR 4307 MALDI-
TOF Mass Spectrometer (AppliedBiosystems, Foster City, CA,
USA). The standard peptide mixture was spotted at the same time to
correct the machine. In peptide mass ﬁngerprint (PMF) map database
searching, Mascot Distiller was used to get the monoisotopic peak list
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searches against the Swiss-Prot databases were performed using Mas-
cot search engine (http://www.matrixscience.com/) with a mass toler-
ance of ±50 ppm. The diﬀerential protein spots identiﬁed by PMF
based on MALDI-TOF-MS were also subjected to analysis of ESI-
Q-TOF-MS (Micromass, Manchester, UK). The samples were loaded
on to a pre-column (320 lm · 50 mm, 5 lm C18 sillica beads, Waters)
at 30 lL/min ﬂow rates for concentrations and fast desalting through a
Waters CapLC autosampler, then eluted to the reversed–phase column
(75 lm · 150 mm, 5 lm, 100A˚, LC Packing) at a ﬂow rate of 200 nL/
min after ﬂow splitting for separation. MS/MS spectra were performed
in data-depended mode in which up to 4 precursor ions above an inten-
sity threshold of 7 counts/s (cps) were selected for MS/MS analysis
from each survey ‘‘scan’’. In tandem mass spectrometry data database
query, the peptide sequence tag (PKL) format ﬁle that generated from
MS/MS was imported into Mascot search engine with a MS/MS toler-
ance of ±0.3 Da.
2.7. Immunoprecipitation and Western blot analysis of p53 interacting
proteins
CNE2 cells (1 107 cells) were lysed in lysis buﬀer (20 mM Tris, pH
7.5, 150 mM NaCl, 1 mM EDTA, 5 mM DTT, 1 % Triton X-100,
2.5 mM Na3VO4, 1 mM PMSF, 5 lg/mL of aprotinin, pepstatin A,
and leupeptin) for 60 min on ice, followed by centrifuging at
11000 · g for 15 min at 4 C to remove cell debris. Then, the concen-
tration of proteins was determined by using Bradford reagent (Bio-
Rad Laboratories). The whole cell lysates (1.0 mg) were precleared
with control (non-immune) serum and 30 ll protein G-Sepherose 4B
(Amersham Biosciences) for 1 h at 4 C. The clariﬁed supernatants
were incubated with 10 ll anti-p53 antibody and 30 ll protein G-
Sepherose 4B overnight at 4 C or incubated with 30 ll protein G-
Sepherose 4B coupled with control non-speciﬁc subclass matched
immunoglobulin as negative control. Immunoprecipitated complexes
were separated on 10% SDS–PAGE gels and transferred to Hybond-
P PVDF membranes (Amersham Biosciences). Western blot analysis
was done with monoclonal antibodies against HSP27 (F-4, Santa CruzFig. 1. Stable suppression of p53 expression in CNE2 cells. (A) Schematic di
expression vector pSUPER, sequence of the chemically synthesized siRNA e
human p53 transcripts generated from pSUPER/sip53. (B) Western blot dete
(lane 3) induced a marked reduction in p53 synthesis (top panel). The seco
loading (second panel).Biotechnology, CA, USA) and HSP70 (W27, Santa Cruz Biotechnol-
ogy, CA, USA), and polyclonal antibodies against GRP75 (C-19, San-
ta Cruz Biotechnology, CA, USA) and GRP78 (C-20, Santa Cruz
Biotechnology, CA, USA) described above.
2.8. HSP 27 antisense oligonucleotides (ASOs) treatment of cancer cells
HSP27 antisense phosphorothioate oligodeoxynucleotide and a
scrambled oligonucleotide were synthesized by Takara, Japan. The se-
quence of HSP27 ASO used corresponded to the human HSP27 trans-
lation initiation site (5 0-GGGACGCGGCGCTCGGTCAT-3 0) as
described by Rocchi et al. [13]. A scrambled oligonucleotide (5 0-CAG-
CGCTGACAACAGTTTCAT-3 0) was used as a control. The day be-
fore transfection, CNE2 cells were plated into 6-well at the density of
105 cells/ml medium, grown to about 40–50% conﬂuence, and exposed
to either HSP27 ASO or scrambled ASO (ﬁnal concentration, 200 nM)
preincubated for 20 min with Oligofectamine transfection reagent in
RPMI1640. As mock transfection, cells were exposed to Oligofecta-
mine alone in the absence of antisense and scrambled oligonucleotides.
After 24 h incubation, the expression levels of HSP27 and p53 were
determined by Western blot analysis described above.3. Result
3.1. Establishing p53-knocked down nasopharyngeal carcinoma
cell lines
We used the H1 promoter to drive expression of siRNA tar-
geting human p53 (Fig. 1A). The target sequence was cloned
into the BglII/HindIII sites of pSUPER vector, which is pre-
dicted to produce the depicted transcript, and the conﬁgura-
tion of the construct pSUPER/sip53 was veriﬁed by DNA
sequencing. After transfecting pSUPER/sip53 plasmid or pSU-
PER vector into CNE2 cells, puromycin-resistant CNE2 cellagram of siRNA expressing system. Schematic structure of the siRNA
ncoding DNA oligonucleotides and predicted structure of shRNA for
ction of p53 expression. Stable expression of p53 siRNA in CNE2sip53
nd blot was probed with anti-b-Actin antibody to control for protein
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mycin for two weeks. Then, the positive clones were picked
and expanded to establish cell lines, and the expression levels
of p53 were detected by Western blot analysis. As showed in
Fig. 1B, CNE2sip53 cell line stably transfected with pSU-
PER/sip53 plasmid was eliminated the p53 expression, while
the expression level of p53 protein in CNE2/pSUPER cell line
transfected with pSUPER plasmid did not change. These re-
sults suggested that vector-delivered siRNA could trigger
downregulation of p53 genes in an eﬃcient and sequence-spe-
ciﬁc manner in CNE2 cells.
3.2. 2-D gel analysis of diﬀerentially expressed proteins
To identify the proteins associated with the function of p53
in NPC, we initiated a comparative proteomic study of CNE2-
sip53 and CNE2/pSUPER cell lines. In the preliminary exper-
iment, 2-DE maps of CNE2/pSUPER and CNE2sip53 was
performed using pH 3–10 IPG strips for the ﬁrst dimension.
After several repeated runs, we found that most of the diﬀeren-
tially expressed proteins were included in the pH range from 4
to 7. To isolate these proteins more eﬃciently, the narrow pH
4–7 IPG strips for the ﬁrst dimension were used to better sep-
arate the total proteins. In the pH range 4–7, two representa-Fig. 2. 2-DE maps of CNE2/pSUPER and CNE2sip53. (A) Representative 2
expression proteins spots marked with arrows were identiﬁed using both M
diﬀerential expression protein spots between CNE2/pSUPER and CNE2sip5tive 2-DE maps from CNE2/pSUPER and CNE2sip53 were
shown in Fig. 2A. For a reliable analysis of protein expression,
2-DE of each cell line was performed in triplicate. The attained
2-DE patterns of each cell line were highly reproducible and
well-resolved. The 2-DE maps of CNE2sip53 and CNE2/pSU-
PER displayed about 1100 protein spots each. Close-up of the
region of the gels showing diﬀerential expression proteins be-
tween CNE2sip53 and CNE2/pSUPER was shown in
Fig. 2B. Image analysis revealed that 14 spots (9, 14, 19, 21,
etc.) were speciﬁcally upregulated (P 2-fold upregulated;
P < 0:05) in the CNE2sip53 while 8 spots (7, 15, 16, etc.) were
decreased (P 2-fold downregulated; P < 0:05) in comparison
with the expression in CNE2/pSUPER, among which some
protein spots such as spots 1 and 2 present as trains of similar
molecular weight, but diﬀerent pIs indicative of post-transla-
tional modiﬁcations (Fig. 2A).
3.3. Identiﬁcation of diﬀerential expression proteins by
MALDI-TOF-MS and ESI-Q-TOF-MS
The 22 diﬀerentially expressed protein spots, marked with
the numbers and arrows in Fig. 2A, were excised from Coo-
massie Brilliant Blue-stained gels, in situ digested with trypsin
and analyzed by MALDI-TOF-MS and ESI-Q-TOF-MS.-DE maps of CNE2/pSUPER and CNE2sip53. Twenty-two diﬀerential
ALDI-TOF-MS and ESI-Q-TOF-MS. (B) Close-up image of partial
3.
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ferentially expressed protein were identiﬁed. The MALDI-Fig. 3. MALDI-TOF-MS and ESI-Q-TOF-MS analysis of diﬀerential expres
19 identiﬁed as the HSP27 according to the matched peaks was shown. (B
indicated in red color and underlined. (C) The ESI-Q-TOF-MS sequenced spe
with m/z 954.1473 was identiﬁed as LATQSNEITIPVTFESR from mass diﬀe
of HSP27. (D) Protein sequence of HSP27 was shown, and matched MS/MSTOF mass spectrometry map and database query result of a
representative spot 19 are shown in Fig. 3A and B, respectively.sion protein spot 19. (A) The MALDI-TOF-MS mass spectrum of spot
) Protein sequence of HSP27 was shown, and matched peptides were
ctrum of spot 19. The amino acid sequence of a doubly charged peptide
rences in the y-fragment ions series, and matched with residues 172–188
fragmentation was underlined.
Table 1
MALDI-TOF-MS and ESI-Q-TOF-MS identiﬁed proteins in CNE2/pSUPER vs. CNE2sip53 comparison
Spot No Accession number Protein name %Cov a Scorea Est.
mass
(Da)
Est.
pI
Pred.
mass
(Da)
Predt.
pI
CNE2sip53
vs.CNE2/pSUPER
Function
Av. ratio P-value
1 A29821 dnaK-type
molecular chaperone
HSPA5 precursor
(GRP78)
39 252 77400 4.8 72185 5.03 2.10 0.001 Chaperone
2 A29821 dnaK-type
molecular chaperone
HSPA5 precursor
(GRP78)
43 211 77400 4.86 72185 5.03 2.35 0.001 Chaperone
3 T02243 Probable
transitional
endoplasmic
reticulum ATPase
50 242 84900 5.15 89950 5.14 2.13 0.002 Metabolism
4 P61978 Heterogeneous
nuclear
ribonucleoprotein K
(hnRNP K)
57 189 68200 5.17 51230 5.39 0.38 0.002 Signal
transduction
5 Q53HF2 Heat shock 70 kDa
protein 9B precursor
40 161 75400 5.36 73920 5.87 2.33 0.001 Chaperone
6 AAA67526 GRP75 44 204 75000 5.58 74019 5.97 0.50 0.001 Chaperone
7 S12566 Translation
initiation factor
eIF4B
22 72 74700 5.72 69240 5.49 0.43 0.01 Transcription
and translation
8 P05783 Cytokeratin 18 67 275 48000 5.4 47305 5.27 2.08 0.008 Cytoskeleton
9 Q6P4C7 Cytokeratin 8 69 216 58200 5.64 55874 5.62 2.74 0.027 Cytoskeleton
10 S68363 Protein disulﬁde-
isomerase ER60
precursor
49 165 61700 5.81 57146 5.98 2.01 0.037 Metabolism
11 P05388 Ribosomal protein
P0
33 135 43100 5.83 34424 5.42 2.87 0.010 Signal
transduction
12 Q15181 Inorganic
pyrophosphatase
37 69 34500 5.39 33095 5.54 3.01 0.001 Metabolism
13 P02647 Crystal structure of
lipid-free human
apolipoprotein A–I
39 71 32700 5.43 28061 5.27 0.47 0.003 Metabolism
14 P07195-00-09-00 (LDHB_HUMAN)
Splice isoform
displayed
35 79 37500 5.79 36655 5.72 3.51 0.013 Metabolism
15 Q07955 Splicing factor,
arginine/serine-rich
1(SFRS1) protein
50 82 29300 5.11 22560 7.72 0.31 0.001 Signal
transduction
16 Q07955 Splicing factor,
arginine/serine-rich
1(SFRS1) protein
50 94 28700 5.21 22560 7.72 0.34 0.001 Signal
transduction
17 P31947 14-3-3 protein sigma
(Stratiﬁn) (epithelial
cell marker protein
1)
60 137 27300 4.45 27871 4.68 2.55 0.002 Signal
transduction
18 P35232 Prohibition 84 240 28000 5.56 29859 5.57 0.48 0.001 Signal
transduction
19 E980237 Heat shock protein
27
78 122 25700 6.17 22427 7.83 2.5 0.001 Chaperone
20 P31942 Heterogeneous
nuclear
ribonucleoprotein
H3 (hnRNP H3)
51 110 25200 6.54 31505 6.76 2.01 0.004 Signal
transduction
21 O43169 Cytochrome b5 49 75 21300 4.53 16436 4.78 2.21 0.009 Metabolism
22 Q5W0H4 Tumor protein,
translationally-
controlled 1 (TPT1)
59 125 20000 4.66 21626 5.34 0.48 0.02 Transcription
and translation
Diﬀerentially labelled proteins form 2D analysis were identiﬁed by MALDI-TOF peptide mass ﬁngerprinting and ESI-Q-TOF-MS. The % coverage
of analyzed peptides, the score from Mascot searches, the estimated mass and pI (from gels), the predicted mass and pI (from the database) and
Swiss-Prot accession number are shown for each protein. Proteins displaying an average fold-diﬀerence of P 2-fold up (+) or down () regulation
between pairs of conditions where P < 0:05.
aMALDI-TOF result of % coverage of analyzed and the score from Mascot searches.
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search engine to search the Swiss-Prot database, and the queryresult showed that protein spot 19 was HSP27. The MS/MS re-
sults of spot 19 are shown in Fig. 3C and D. The amino acid
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954.1473 was identiﬁed as LATQSNEITIPVTFESR, which
was a part of HSP27 sequence, and the query result indicated
that protein spot 19 was HSP27. The annotation of all the iden-
tiﬁed proteins is summarized in Table 1. In this study, Splicing
factor, arginine/serine-rich 1(SFRS1) protein with diﬀerent pIs
were found in spots 1 and 2, and dnaK-type molecular chaper-
one HSPA5 precursor (GRP78) were found in spots 15 and 16
(Fig. 2A), which were contributed possibly by post-transla-
tional modiﬁcations such as phosphorylation events. Based
on protein functions using information from the database of
Swiss-Prot websites, 22 identiﬁed proteins associated with sta-Fig. 5. Sequence-speciﬁc inhibition of HSP27 expression by HSP27 ASO in C
signiﬁcantly reduced HSP27 protein level (lane 3), whereas HSP27 protein ex
(lane 2) or mock transfection (Oligofectamine treatment alone, lane 1). Se
expression of p53 protein (lane 3) as compared to scrambled oligonucleotide
each protein was estimated by densitometry and presented as a ratio to the
triplicate. * P < 0:05 vs. cells transfected with scrambled oligonucleotide or
Fig. 4. Protein–protein interaction analysis of p53 and HSP27 in
CNE2 cells. Cell lysates were immunoprecipitated (IP) with anti-p53
and subjected to Western blotting with antibodies against HSP27,
HSP70, GRP75 and GRP78. HSP27, HSP70, GRP75 and GRP78
were detected in the protein complex of p53 antibody immunoprecip-
itation with CNE2 total proteins (lane 1). Lanes 2 were the protein
complex of control non-speciﬁc subclass matched immunoglobulin
immunoprecipitation with total proteins.ble silence of p53 were categorized into 5 protein groups as sig-
nal transduction, chaperone, transcription and translation,
metabolism and cytoskeleton. Most of the diﬀerentially ex-
pressed proteins were molecular chaperone, and proteins re-
lated to signal transduction or metabolism.
3.4. Identiﬁcation of p53 interacting proteins by
immunoprecipitation and Western blot analysis
To detect the interaction of diﬀerentially expressed proteins
with p53 protein, the whole cell lysates were immunoprecipi-
tated using a monoclonal antibody for p53. The immunopre-
cipitated complex was resolved on denaturing gels, blotted
and analyzed for the presence of HSP27, HSP70, GRP75
and GRP78. As can be seen from the immunoblots shown in
Fig. 4, HSP27, HSP70, GRP75 and GRP78 were detected in
the immunoprecipitated complex of p53 (lane 1). In contrast,
no visible bands of HSP27, HSP70, GRP75 and GRP78 were
detected in control non-speciﬁc subclass matched immuno-
globulin (lane 2). The result veriﬁed that some of diﬀerentially
expressed proteins were interacted with p53 protein in NPC
cells.
3.5. p53 expression was suppressed by HSP27 ASOs
transfection
Previous studies suggested that binding of HSPs family
member, a p53-interacting protein with p53, could increase sta-
bilization of p53 protein, and result in accumulation and inac-
tivation of p53 protein in cancer cells [14,15]. To determine
whether HSP27, one of p53-interacting proteins in CNE2 has
an eﬀect on p53 protein level, CNE2 cells were transfected with
HSP27 ASOs for 24 h, followed by Western blot analysis of
p53 expression level. The result showed that suppression of
HSP27 protein expression by HSP27 ASOs signiﬁcantly re-
duced the p53 protein level in CNE2 cells, whereas the p53
protein levels were not signiﬁcantly suppressed by scrambled
oligonucleotide or Oligofectamine treatment alone (P < 0:05)
(Fig. 5). The result suggested that interaction of HSP27 withNE2 cells. Top panel showed that treatment of cells with HSP27 ASO
pression was not signiﬁcantly suppressed by scrambled oligonucleotide
cond blot showed that HSP27 ASOs treatment led to a decrease of
treatment (lane 2) or mock transfection (lane 1). Expression level for
loading control b-actin (third panel). The experiment was repeated in
mock transfection.
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sult in accumulation of p53 protein in NPC cells.4. Discussion
This study combined a proteomic approach with RNAi tech-
nology to identify proteins associated with the function of p53
in NPC. We successfully used RNAi technology constructing
the pSUPER/sip53 plasmid and stably knocking down p53
gene expression in human undiﬀerentiated NPC cell line
CNE2. As a reliable cell model, the well-resolved, reproducible
2-DE patterns of CNE2sip53 and CNE2/pSUPER were estab-
lished. Twenty-two diﬀerentially expressed proteins spots
between the two cell lines were identiﬁed by both MALDI-
TOF-MS and ESI-Q-TOF-MS. Among them, HSP27, 14-3-
3r, GRP78, HSP70 and so on were upregulated in CNE2sip53
cells, while translation initiation factor eukaryotic translation
initiation factor 4B (eIF4B), tumor protein translationally-
controlled 1 (TPT1), heterogenous nuclear ribonuclear protein
K (hnRNP K) and so on were downregulated. Some of the dif-
ferential expression proteins are known to be associated with
the p53 function (HSP27, hnRNP K, 14-3-3r, etc.), and others
may be novel proteins associated with p53 function (eIF4B,
TPT1, hnRNP H3, SFRS1, etc.). These diﬀerential proteins
would provide new clues to elucidate the mechanisms of inac-
tivation and stabilization of p53 in NPC.
One of the major diﬀerentially expressed proteins groups
was chaperones including members of heat shock proteins
family, such as HSP27, HSP70, GRP75 and GRP78 (Table
1). HSPs comprise several diﬀerent families of proteins that
are induced in response to a wide variety of physiologic and
environmental insults, and enable the cell to survive and re-
cover from stressful conditions [16]. One of primary mecha-
nisms for HSPs regulation involves tumor suppressor protein
p53. Although the precise mechanisms of the regulation of
p53 on HSPs have not been clariﬁed, p53 has been reported
to repress the transcription of HSPs genes by interacting with
a speciﬁc CCAAT binding factor (CBF) that directly binds
with HSPs gene promoter [17,18]. Therefore, increased expres-
sion of HSPs including HSP27, HSP70 and GRP78 in CNE2-
sip53 cell line might result directly from the relief of
transcriptional repression by p53. Furthermore, in our study,
we observed the change of pI and Mr of HSPs such as
HSP27. Such results raise concerns about the eﬀect of protein
post-translational modiﬁcations such as cleavage products or
phosphorylation events induced by p53 silence on the biologi-
cal activity of these products, but more importantly, on their
potential oncogenicity and stress resistant phenotypes. On
the other hand, previous studies suggested that HSPs could in-
crease stabilization of p53 protein, and result in accumulation
and inactivation of p53 protein in cancer cells such as neuro-
blastoma, breast cancer, colon cancer and retinoblastoma
through interaction with p53 protein [14,15,19]. In our study,
anti-p53 immune complexes from CNE2 cell lysates were de-
tected the presence of HSP27, HSP70, GRP75 and GRP78
(Fig. 4) by immunoprecipitation and Western blot analysis,
and the suppression of HSP27 by HSP27 ASO in CNE2 cells
decreased p53 proteins expression (Fig. 5). These results sug-
gested that HSP27, HSP70, GRP75 and GRP78 probably
not only were the target genes of p53, but also were p53-inter-action protein in NPC, and they might stabilize p53 protein by
increasing the half-life of p53 protein, resulting in the accumu-
lation and inactivation of p53 protein in NPC.
The expressions of proteins related to signal transduction
such as hnRNP K and 14-3-3r, and proteins related to tran-
scription and translation such as eIF4B and TPT1 were chan-
ged in CNE2sip53 cell line, which indicated these proteins were
correlated with the p53 function. hnRNP K is an evolution-
arily conserved factor and an RNA-binding protein that was
indicated in processes including chromatin remodeling and
transcription as well as mRNA splicing, export, and transla-
tion [20]. It was reported that hnRNP K, a transcriptional
coactivator of p53 in response to DNA damage, played an
important role in DNA-damage-induced cell cycle arrest by
recruiting to the promoters of p53 target in a p53-dependent
manner, and enhancing the expression of the c-myc, EGR,
and BRCA1 genes [21]. eIF4B can promote RNA-dependent
ATP hydrolysis activity and ATP-dependent RNA helicase
activity of eIF4A and eIF4F during translation initiation
[22]. Activation of p53 results in the caspase-independent
downregulation of translation, together with the cleavages of
at least eIF4GI and eIF4B that are known substrates for pro-
teolysis in apoptotic cells and critical for protein synthesis [23].
TPT1 is a protein which has been found to be preferentially
synthesized in cells during the early growth phase of some
types of tumor, but which is also expressed in normal cells
[24]. In our study, the ﬁnding that downregulation of hnRNP
K, eIF4B and TPT1 in CNE2sip53 cell line indicated that they
might be novel p53-associated proteins and associate with p53
function in NPC.
The expression levels of some metabolic enzymes had obvi-
ous changes in CNE2sip53 cell line. Among them, the expres-
sion level of proteins including cytochrome b5 and probable
transitional endoplasmic reticulum ATPase related to the
metabolism were upregulated in CNE2sip53 cell line, which
suggested an eﬀect of metabolism enhancement in NPC cell
line in agreement with inhibition of expression of p53 tumor-
suppressor protein. Finally, there were still some proteins
including cytoskeleton proteins, which were found to be diﬀer-
entially expressed between CNE2sip53 and CNE2/pSUPER,
have not been linked to p53 previously.
Our study combined a proteomic approach with RNAi tech-
nology to identify proteins associated with the function of p53
in NPC in high throughout screening. Considering the func-
tions of the identiﬁed diﬀerential proteins, it is reasonable to
predict that the proteins such as HSP27, HSP70, hnRNP K,
14-3-3r, and so on were associated with the function of p53
in CNE2. Some have not been shown before to be associated
with p53 (eIF4B, TPT1, hnRNP H3, SFRS1, etc.) and might
be novel p53-associated proteins in NPC. Introducing siR-
NA-mediated gene silencing into proteomics might reveal
novel p53 signal pathway and these ﬁndings provided the basis
to comprehensively investigate the functional mechanisms of
p53 in NPC.
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